Middle East And Africa Neurodegenerative Disease Market Size, Share & Trends Analysis Report By Disease Indication (Multiple Sclerosis, Parkinson's Disease, Alzheimer's Disease, Others), By Drug Type (Immunomodulator, Vesicular Monoamine Transporter 2 (VMAT2), Others), By Routes of Administration (Oral, Intravenous (IV) delivery, Others) and By Country (UAE, Turkey, Saudi Arabia, South Africa, Egypt, Nigeria, Rest of MEA) Forecasts, 2026-2034

Last Updated: July 09, 2026 | Author: Debashree B | Format:

Market Segmentation

  1. Middle East And Africa Neurodegenerative Disease Market, By Disease Indication 2022-2034 (USD MILLION/ Units)
    1. Multiple Sclerosis
    2. Parkinson's Disease
    3. Alzheimer's Disease
    4. Others
  2. Middle East And Africa Neurodegenerative Disease Market, By Drug Type 2022-2034 (USD MILLION/ Units)
    1. Immunomodulator
    2. Vesicular Monoamine Transporter 2 (VMAT2)
    3. Others
  3. Middle East And Africa Neurodegenerative Disease Market, By Routes of Administration 2022-2034 (USD MILLION/ Units)
    1. Oral
    2. Intravenous (IV) delivery
    3. Others
  4. Regional Middle East And Africa Neurodegenerative Disease Market
    1. Middle East and Africa
      1. Middle East and Africa Middle East And Africa Neurodegenerative Disease Market By Disease Indication 2022-2034 (USD MILLION/ Units)
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
      2. Middle East and Africa Middle East And Africa Neurodegenerative Disease Market By Drug Type 2022-2034 (USD MILLION/ Units)
        1. Immunomodulator
        2. Vesicular Monoamine Transporter 2 (VMAT2)
        3. Others
      3. Middle East and Africa Middle East And Africa Neurodegenerative Disease Market By Routes of Administration 2022-2034 (USD MILLION/ Units)
        1. Oral
        2. Intravenous (IV) delivery
        3. Others
      4. UAE
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
      5. Turkey
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
      6. Saudi Arabia
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
      7. South Africa
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
      8. Egypt
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
      9. Nigeria
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others
      10. Rest of MEA
        1. Multiple Sclerosis
        2. Parkinson's Disease
        3. Alzheimer's Disease
        4. Others
        5. Immunomodulator
        6. Vesicular Monoamine Transporter 2 (VMAT2)
        7. Others
        8. Oral
        9. Intravenous (IV) delivery
        10. Others

We are featured on: